Skiplinks

Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

High-risk medical devices: IQWiG sees no potential in 6 of 8 cases

2017-03-17 Only case series without informative value are available for most indications. A plausible mode of action is insufficient to attribute a potential.  read more Link to "High-risk medical devices: IQWiG sees no potential in 6 of 8 cases"

MRI-guided high-intensity focused ultrasound therapy for uterine fibroids has potential

2017-03-13 IQWiG has attributed a potential for a benefit to a new treatment method according to §137e SGB V. A testing study has been initiated. Numerous other assessments had no consequences.  read more Link to "MRI-guided high-intensity focused ultrasound therapy for uterine fibroids has potential"

Tonsillotomy: fewer adverse effects in the short term, but renewed inflammation and surgery possible

2017-03-03 In the short term, tonsillotomy is associated with less pain, as well as fewer swallowing and sleeping problems, than tonsillectomy. But regrowing tissue can lead to renewed inflammation.  read more Link to "Tonsillotomy: fewer adverse effects in the short term, but renewed inflammation and surgery possible"

Palbociclib in advanced breast cancer: Disadvantages predominate in certain patients

2017-03-01 More severe side effects occur under the combination of palbociclib and letrozole in the first-line treatment of postmenopausal women. Data were lacking for other patient groups.  read more Link to "Palbociclib in advanced breast cancer: Disadvantages predominate in certain patients "

loading …

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No. Title Type Deadline
A16-70 Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis on the report plan 2017-03-29

Commissions advertised

Commissions advertised

Currently no commissions advertised.


Easily understandable information for patients and the general community

Palbociclib (Ibrance) for advanced breast cancer

Palbociclib (trade name: Ibrance) has been approved in Germany since November 2016 for the treatment of advanced hormone receptor-positive breast cancer in women who cannot have chemotherapy, radiotherapy or further surgery.  read more (Link to "Palbociclib (Ibrance) for advanced breast cancer" – opens in a new window)

to top

Glossary entries